



CECORS INC.

AMENDED INFORMATION AND DISCLOSURE STATEMENT

RULE 15c2-11

PURSUANT TO THE SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 31, 2021

Nevada	1311
(State or Jurisdiction of incorporation)	(SIC Code)

190 Norseman St. Suite 100 Etobicoke, ON M8Z 2R4
(Address of principal executive offices)

(888) 376-8258
(Issuer's telephone number, including area code)

All information in this Information and Disclosure Statement has been completed to fulfill the disclosure requirements of Rule 15c2-11 as promulgated under the Securities and Exchange Act of 1934, as amended. The information supplied corresponds to the format as set forth in 15c2-11(a)(5).

CHANGE OF SHELL STATUS

CeCors, Inc. a Nevada corporation (the "Company"), is filing this Amended Supplemental Information and Disclosure Statement to notify shareholders that the Company is no longer a "shell company" as defined by Rule 405 of the Securities Act of 1933 ("Rule 405"). Rule 405

defines a "shell company" as an issuer that has: (1) no or nominal operations; and (2) either: (i) no or nominal assets; (ii) assets consisting solely of cash and cash equivalents; or (iii) assets consisting of any amount of cash and cash equivalents and nominal other assets.

As of the quarterly report for the period ended September 30, 2021, the Company showed little cash, no revenues, no inventory, and minimal operating expenses, primarily attributed to general and administrative costs. Accordingly, we believe that our financial statements for the nine-month period ended September 30, 2021, represented those of a "shell company."

In May 2021, the Company, through its wholly-owned subsidiary, PsyKey, entered into a definitive agreement to form an exclusive strategic partnership with MycoVita Canada Inc. ("MycoVita"), which is expected to accelerate the growth and market share for both companies, in the fast-growing mycology-based markets. The partnership is undertaken through a 51% controlled subsidiary of PsyKey, Fungi Co Ltd., a Canadian federal incorporation, with the purpose of the partnership being the research, development, and commercialization of Mycology based formulations, products, and therapeutics, as well as the development of innovative sustainable food production strategies. Recently, the Company commenced operations in Fungi through issuing its first purchase orders to MycoVita for raw materials, which arrived in Spring 2022. The Company also received its first customer purchase order in December 2021 for 1,850 boxes of coffee pods, of which 900 boxes were delivered in July 2022.

During the fiscal year ended December 31, 2021, the Company agreed to pay certain software development consultants a total of \$500,000 for the work product related to the currently in-development APP, "PsyKey Live." The App will provide counseling on demand at any time and location with registered psychologists in every area of mental wellness, allowing individuals to take control of their mental health. Offering simple, direct access to caring mental health professionals for all conditions, from daily challenges to more severe treatments, the App will allow users to book an appointment on their phone or desktop to receive immediate counseling.

During the quarter ended March 31, 2022, the Company entered into agreements to acquire a 100% equity interest in Nutra-Rox, LLC. ("NRX"), a company incorporated in Texas in exchange for common shares of the Company's common stock. Nutra-Rox is a disruptive thought leader in the dietary supplement industry; its functional carbonated crystal delivery technology allows for bioavailable ingredients such as functional mushrooms, adaptogens, and nootropics to be delivered via "popping" carbonated crystals. Nutra-Rox is also the developer of Breath Rox®, a sugar-free popping fresh breath treatment that delivers zinc gluconate to help reduce odor-causing bacteria in the mouth. The Nutra-Rox management team has over 50 years of collective experience in research, product development, manufacturing, branding, marketing, sales, and distribution. The Nutra-Rox acquisition will provide the Company with expanded novel product offerings, sales, and distribution. The Company is in the final stages, pending delivery of GAAP compliant financial statements, of closing the acquisition of Nutra-Rox, LLC.

The Company's "PsyKey" brand and products utilize premium quality mushrooms, complete with certificates of analysis from approved producers. Six functional mushroom strains are used in the development of the Company's retail product offerings; they include 150 kilograms of each Ganoderma, Turkey Tail, Cordyceps, Maitake, Lions Mane, and Chaga. A highly qualified

mycologist has overseen the procurement of 150kg of each of our functional mushroom ingredients, and delivery of these raw materials to our manufacturing partner, MyCovita, took place in Q2 2022.

The Company's initial product line consists of coffee pods and ground coffee bags. Coffee pods are single serving pods sealed with a foil and served in a box of 24 pods. Each pod contains 500mgs of mushrooms for an infused functional benefit per serving. The Company's functional mushroom-infused coffees are created by combining the highest quality 100% fair trade organic Arabica coffee beans with amazing functional mushrooms that have been used for their benefits for centuries. Additionally, PsyKey's functional coffee formulation is developed utilizing dried ground fruiting body, "Actual Mushrooms," intended to provide the full potential of each functional mushroom when brewed.

As of the fiscal year ended December 31, 2021, along with the first and second quarters of 2022, the Company had cash on hand, inventory, and/or prepaid expenses to acquire inventory. As our most recent quarter ended June 30, 2022, we reported total assets in the amount of \$615,616 (December 31, 2021 - \$626,705). In addition, the Company commenced selling its branded coffee pods online via WooCommerce and continues receiving orders for its coffee products, generating revenues and increasing sales.

We believe that our financial reports for the Annual report ended December 31, 2021, and each of our filed interim reports thereafter reflect substantive operations that indicate we are no longer a "shell company." Although the definition of "shell company" does not include revenues specifically, it is generally understood that revenues are a good indication of actual operations. As reported in our most recent quarterly report ended June 30, 2022, we have commenced revenue-generating operations. In addition to intangible assets of \$500,000 at each reporting period, the Company has reported substantive current assets, including cash, prepaid expenses, inventory, and/or accounts receivable.

Therefore, as of December 31, 2021, the Company was no longer considered a "shell company" as defined by Rule 405 of the Act, having shown evidence of actual operations through the Company's offered services and products, as noted *and* by virtue of the fact that we have had and continue to have, greater than nominal assets.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CeCors, Inc.

(Issuer)

Date: August 24, 2022

By: 

Name: Mr. Sukhinder Kalsi

Title: Chief Financial Officer/Director